Genetic aberrations in squamous cell carcinoma of the head and neck (SCCHN), with reference to oral carcinoma (Review)

International Journal of Oncology

Volumn 10, Issue 1, 1997, Pages 5-21

  Scully, Crispian ^a   Field, John K ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Head and neck cancer; Oral carcinoma; Squamous cell carcinoma

Indexed keywords

GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0031017764     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.1.5     Document Type: Review

References (324)

1. Burkhardt A: Advanced methods in the evaluation of premalignant lesions and carcinomas of the oral mucosa. J Oral Pathol 14: 751-778, 1985.
2. Field JK: Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur J Cancer Oral Oncol 28B: 67-76, 1992.
3. Field JK and Spandidos DA: Oncogenes and tumour suppressor genes as prognostic indicators in the development of human tumours. In: Regulation and Proliferation of Neoplastic Cells. Pusztai L, Lewis CE and Yap E (eds). Vol. 1. Oxford University Press, Oxford, pp59-78, 1995.
4. Somers KD and Schechter GL: Genetic alterations in head and neck cancer. Otolaryngol Clin N Amer 25: 1065-1071, 1992.
5. Scully C: Oncogenes, tumour suppressors and viruses in oral squamous carcinoma. J Oral Pathol Med 22: 337-347, 1993.
6. Sugerman PB, Joseph BK and Savage NW: Review article: the role of oncogenesis, tumour suppressor genes and growth factors in oral squamous cell carcinoma: a case of apoptosis versus proliferation. Oral Diseases 1: 172-188, 1995.
7. Johnson NW, Ranasinghe AW and Warnakulasuriya KAAS: Potentially malignant lesions and conditions of the mouth and oropharynx: natural history - cellular and molecular markers of risk. Eur J Cancer Prevent 2 (Suppl 2): 31-51, 1993.
8. Ravindran T, Vijayakumar T, Sudha L, et al: Chromosome abnormalities in squamous cell carcinoma of the human oral cavity. Neoplasma 37:191-197, 1990.
9. Jin Y, Mertens F, Jin C, Akervall J, Wennerberg J, Gorunova L, Mandahl N, Heim S and Mitelman F: Nonrandom chromosome abnormalities in short-term cultured primary squamous cell carcinomas of the head and neck. Cancer Res 55: 3204-3210, 1995.
10. Cowan JM: Cytogenetics in head and neck cancer. Mol Biol Genet 25: 1073-1087, 1992.
11. Li XH, Lee NK, Ye YW, Waber PG, Schweitzer C, Cheng QC and Nisen PD: Allelic loss at chromosomes 3p, 8p, 13q, and 17p associated with poor prognosis in head and neck cancer. J Natl Cancer Inst 86: 1524-1529, 1994.
12. Ah-See KW, Cooke TG, Pickford IR, Soutar D and Balmain A: Allelotype of squamous carcinoma of the head and neck using microsatellite. Cancer Res 54: 1617-1621, 1994.
13. Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM and Sidransky D: Allelotype of head and neck squamous cell carcinoma. Cancer Res 54: 1152-1155, 1994.
14. Field JK, Kiaris H, Risk JM, Tsiriyotis C, Adamson R, Zoumpourlis V, Rowley H, Taylor K, Whittaker J, Howard P, Beirnie JC, Gosney JR, Woolgar J, Vaughan ED, Spandidos DA and Jones AS: Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival. Br J Cancer 72: 1180-1188, 1995.
15. Bodmer WF: Cancer genetics. Br Med Bull 50: 517-526, 1994.
16. Fuzesi L, Braun S, Gunawan B, Schmitz HJ and Mittermayer C: Cytogenetic findings in squamous cell carcinoma of the oral cavity. Int J Oral Maxillofac Surg 23: 155-153, 1994.
17. Rao PH, Sreekantaiah C, Schamntz SP and Chaganti RS: Cytogenetic analysis of 11 squamous cell carcinomas of the head and neck. Cancer Genet Cytogenet 77: 60-64, 1994.
18. Sreekantaiah C, Rao PH, Xu L, Sacks PG, Schantz SP and Chaganti RSK: Consistent chromosomal losses in head and neck squamous cell carcinoma cell lines. Genes Chromosom Cancer 11: 29-39, 1994.
19. van Dyke DL, Worsham MJ, Benninger MS, et al: Recurrent Cytogenetic abnormalities in squamous cell carcinoma in South African Indians: a retrospective study. S Afr Med J 83: 425-429, 1993.
20. van Dyke DL, Worsham MJ, Benninger MS, Krause CJ, Baker SR, Wolf GT, Drumheller T, Tilley BC and Carey TE: Recurrent Cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosom Cancer 9: 192-206, 1994.
21. Adhvaryu SG, Dave BJ and Trivedi AH: Cytogenetic surveillance of tobacco-areca nut (mava) chewers, including patients with oral cancers and premalignant conditions. Mutat Res 261: 41-49, 1991.
22. Kao-Shan CS, Fine RL, Whang-Peng J, Lee EC and Chabner BA: Increased fragile sites and sister chromatid exchanges in bone marrow and peripheral blood of young cigarette smokers. Cancer Res 47: 6278-6282, 1987.
23. Cloos J, Spitz MR, Schants SP, et al: Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 530-535, 1996.
24. De Vries N, De Lange G, Drexhage HA and Snow GB: Immunoglobin allotypes in head and neck cancer patients with multiple primary cancers. Acta Oto-laryngol 104: 187-191, 1987.
25. De Vries N, De Waal LP, De Lange G, Drexhage HA and Snow GB: HLA antigens and immunoglobulin allotypes in head and neck cancer patients with and without multiple primary tumors. Cancer 60: 957-961, 1987.
26. Spitz MR, Fueger JJ, Beddingfield NA, Annegers JF, Hsu TC, Newell GR and Schantz SP: Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res 49: 4626-4628, 1989.
27. Spitz MR, Fueger JJ, Halabi S, Schantz SP, Sample D and Hsu TC: Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidem Biomarker Prev 2: 329-333, 1993.
28. Schantz SP, Spitz MR and Hsu TC: Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J Natl Cancer Inst 82: 1773-1775, 1990.
29. Cloos J, Braakhuis BJM, Steen I, Copper MP, De Vries N, Nauta JJP and Snow GB: Increased mutagen sensitivity in head and neck squamous cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer 56: 816-819, 1994.
30. Bondy ML, Spitz MR, Halibi S, et al: Association between family history of cancer and mutagen sensitivity in upper aerodigestive tract cancer patients. Cancer Epidem Biomarker Prev 2: 103-106, 1991.
31. Bazopoulou-Kyrkanidou E, Garas J and Angelopoulos AP: SCE in lymphocytes of patients with oral carcinoma. Cancer Genet Cytogenet 20: 35-38, 1986.
32. Trivedi AH, Bhavana JD and Adhvaryu SG: Monitoring of smokeless tobacco consumers using cytogenetic endpoints. Anticancer Res 13: 2245-2250, 1993.
33. Popp W, Schell C, Kraus R, Vahrenholz C, Wolf R, Radtke J, Bierwirth K and Norpoth K: DNA strand breakage and DNA adducts in lymphocytes of oral cancer patients. Carcinogenesis 14: 2251-2256, 1993.
34. Popp W, Wolf R, Vahrenholz C, Radtke J, Schell C, Kraus R, Brauksiepe G and Norpoth K: Sister chromatid exchange frequencies in lymphocytes of oral cancer patients seem to be influenced by drinking habits. Carcinogenesis 15: 1603-1607, 1994.
35. Hermsen MAJA, Joenje H, Arwert F, et al: Centromeric breakage as a major cause of cytogenetic abnormalities in, oral squamous cell carcinoma. Genes Chromosom Cancer 15: 1-9, 1996.
36. Jin Y and Mertens F: Chromosome abnormalities in oral squamous cell carcinomas. Oral Oncol Eur J Cancer 29B: 257-263, 1993.
37. Jin Y, Hein S, Mandahl N, Biorklund A, Wennerberg J and Mitelman F: Unrelated clonal chromosomal aberrations in carcinomas of the oral cavity. Genes Chromosom Cancer 1: 209-215, 1990.
38. Jin Y, Higashi K, Mandahl N, et al: Frequent arrangement of chromsomal bands 1p22 and 11q13 in squamous cell carcinomas of the head and neck. Genes Chromosom Cancer 2: 198-204, 1990.
39. Jin Y, Mertens F, Mandahl N, Heim S, Olegard C, Wennerberg J, Bjorklund A and Mitelman F: Chromosome abnormalities in eighty-three head and neck squamous cell carcinomas: influence of culture conditions on karyotypic pattern. Cancer Res 53: 2140-2146, 1993.
40. Owens W, Field JK, Howard PJ and Stell PM: Multiple cytogenetic aberrations in squamous cell carcinomas of the head and neck. Oral Oncol Eur J Cancer 28B: 17-21, 1992.
41. Emilion G, Langdon JD, Speight P and Partridge M: Frequent gene deletions in potentialy malignant oral lesions. Br J Cancer 73: 809-813, 1996.
42. Roz L, Wu CL, Porter SR, Scully C, et al: Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral Carcinogenesis. Cancer Res 56: 1228-1231, 1996.
43. Ishwad CS, Ferrell RE, Rossie KM, et al: Loss of heterozygosity of the short arm of chromosomes 3 and 9 in oral cancer. Int J Cancer 69: 1-4, 1996.
44. Maestro R, Piccinin S, Doglioni C, et al: Chromosome 13q deletion mapping in head and neck squamous cell carcinomas: identification of two distinct regions of preferential loss. Cancer Res 56: 1146-1150, 1996.
45. Partridge M, Emilion G and Langdon JD: LOH at 3p correlates with a poor survival in oral squamous cell carcinoma. Br J Cancer 73: 366-371, 1996.
46. Rowley H, Jones A, Spandidos D and Field J: Definition of a tumor suppressor gene locus on the short arm of chromosome 3 in squamous cell carcinoma of the head and neck by means of microsatellite markers. Arch Otolaryngol Head Neck Surg 122: 497-501, 1996.
47. Waber PG, Lee NK and Nisen PD: Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the Von-Hippel Lindau tumor suppressor gene in head and neck cancer. Oncogene 12: 365-369, 1996.
48. Lee JS, Kim SY, Hong WK, Lippman SM, Ro JY, Gay ML and Hittelman WN: Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. J Natl Cancer Inst 85: 1951-1954, 1993.
49. Ishwad CS, Ferrell RE, Rossie KM, et al: Microsatellite instability in oral cancer. Int J Cancer 64: 332-335, 1995.
50. Moroco JR, Solt DB and Polverini PJ: Sequential loss of suppressor genes for three specific functions during in vivo carcinogenesis. Lab Invest 63: 298-306, 1990.
51. Suzui M, Yoshimi N, Tanaka T and Mori H: Infrequent Ha-ras mutations and absence of Ki-ras, N-ras and p53 mutations in 4-nitroquinoline 1-oxide-induced rat oral lesions. Mol Carcinogen 14:294-298, 1995.
52. Shintani S, Matsumura T, Alcalde RE and Yoshihama Y: Sequential expression of myc-, ras-, oncogene products and EGF receptor during DMBA-induced tongue carcinogenesis. Int J Oncol 8: 821-826, 1996.
53. Chang K-W, Lin S-C, Koos S, Pather K and Solt D: P53 and Ha-ras mutations in chemically induced hamster buccal pouch carcinomas. Carcinogenesis 17: 595-600, 1996.
54. Hauser-Urfer IF and Stauffer J: Comparative chromosome analysis of nine squamous cell carcinoma cell lines from tumors of the head and neck. Cytogenet Cell Genet 39: 35-39, 1985.
55. Easty DM, Easty GC, Bacici A, et al: Biological studies on ten human squamous cell lines: an overview. Eur J Cancer Clin Oncol 22: 617-634, 1986.
56. Tharapel SA, Norwood M and Lester EP: Non random abnormalities of chromosomes 1 and 11 in squamous cell carcinoma of the head and neck region. Am Soc Hum Genet 43 (Suppl): abs. 34, 1988.
57. Sacks PG, Parnes SM, Gallick GE, Mansouri Z, Lichtner R, Satya-Prakash KL, Pathak S and Parsons DF: Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res 48: 2858-2866, 1988.
58. rd International Head and Neck Oncology Research Conference 9: abs. 2, 1990.
59. Sundqvist K, Kulkarni P, Hybbinette SS, Bertolero F, Liu Y and Grafstrom RC: Serum-free growth and karyotype analyses of cultured normal and tumorous (Sq CC/Y1) human buccal epithelial cells. Cancer Commun 3: 331-340, 1991.
60. Loughran O, Edington KG, Berry IJ, Clark LJ and Parkinson EK: Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes. Cancer Res 54: 5045-5049, 1994.
61. Partridge M, Kiguwa S and Langdon JD: Frequent deletion of chromosome 3p in oral squamous cell carcinoma. Oral Oncol Eur J Cancer 30B: 248-251, 1994.
62. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittleman W and Hong WK: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Med 2: 682-685, 1996.
63. Heo DS, Synderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB and Whitesude TL: Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous carcinoma lines. Cancer Res 49: 5167-5175, 1989.
64. Latif F, Fivash M, Glenn G, Tory K, Orcutt ML, Hampsch K, Kelisio J, Lerman M, Cowan H, Beckett M and Weichselbaum R: Chromosome 3p deletions in head and neck carcinomas: statistical ascertainment of allelic loss. Cancer Res 52: 1451-1456, 1992.
65. El-Naggar AK, Lee M, Wang G, et al: Polymerase chain reactionbased restriction fragment length polymorphism analysis of the short arm of chromosome 3 in primary head and neck squamous carcinoma. Cancer 72: 881-886, 1993.
66. Lydiatt WM, Davidson BJ, Shah J, Schantz SP and Chaganti RSK: The relationship of loss of heterozygosity to tobacco exposure and early recurrence in head and neck squamous-cell carcinoma. Am J Surg 168: 437-440, 1994.
67. Cowan JM, Beckett MA, Ahmed-Swan S and Weichselbaum RR: Cytogenetic evidence of the multistep origin of head and neck squamous cell carcinomas. J Natl Cancer Inst 84: 793-797, 1992.
68. Maestro R, Gasparotto D, Vukosavljevic T, Barzan L, Sulfaro S and Boiocchi M: Three discrete regions of deletion at 3p in head and neck cancers. Cancer Res 53: 5775-5779, 1993.
69. Ishwad CS, Ferrell RE, Rossie KM, Appel BN, Johnson JT, Myers EN, Law JC, Srivastava S, Gollin SM: Loss of heterozygosity of the short arm of chromosomes 3 and 9 in oral cancer. Int J Cancer 69: 1-4, 1996.
70. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee B, Greenberg B, Koch W and Sidransky D: Genetic progression model for head and neck cancer; implications for field cancerization. Cancer Res 56: 2488-2492, 1996.
71. Field JK, Tsiriyotis C, Zoumpourlis V, Howard P, Spandidos DA and Jones AS: Allele loss on chromosome 3 in squamous cell carcinoma of the head and neck correlates with poor clinical prognostic indicators. Int J Oncol 4: 543-549, 1994.
72. Smeets DFCM, Scheres JMJC and Hustinx TWJ: The most common fragile site in man is 3p14. Hum Genet 72: 215-220, 1986.
73. Wu C-L, Sloan P, Read AP, Harris R and Thakker N: Deletion mapping on the short arm chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res 54: 6484-6488, 1994.
74. Uzawa N, Yoshida MA, Oshimura M and Ikeuchi T: Suppression of tumorigenicity in three different cell lines of human oral squamous cell carcinoma by introduction of chromosome 3p via microcell-mediated chromosome transfer. Oncogene 11: 1997-2004, 1995.
75. Largey JS, Meltzer SJ, Sauk JJ, Hebert CA and Archibald DW: Loss of heterozygosity involving the APC gene in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol 77: 260-263, 1994.
76. Uzawa K, Yoshida H, Susuki H, Tanzawa H, Shimazaki J, Senio S and Sato K: Abnormalities in the adenomatous polyposis coli gene in human oral squamous cell carcinoma. Int J Cancer 58: 814-817, 1994.
77. Voravud N, Shin DM, Ro JY, Lee JS, Hong WK and Hittelman WN: Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumorigenesis. Cancer Res 53: 2874-2883, 1993.
78. Todd R, Donoff BR, Gertz R, et al: TGF-α and EGF receptor mRNAs in human oral cancers. Carcinogenesis 10: 1553-1556, 1989.
79. Shirasuna K, Hayashido Y, Sugiyama M, Yoshioka H and Matsuya T: Immunohistochemical localization of epidermal growth fact (EGF) and EGF receptor in human oral mucosa and its malignancy. Virchows Arch (A) 418: 349-353, 1991.
80. Kunikata M, Yamada K, Yamada T, Mori M, Tatemoto Y and Osaki T: Epidermal growth factor receptor in squamous cell carcinoma and other epidermal lesions of squamous origin: an immunohistochemical study. Acta Histochem Cytochem 25: 387-394, 1992.
81. Kuttan NAA, Zhang L, Rosin MP, Bhakthan NMG and Priddy RW: The value of epidermal growth factor receptor (EGFR) as a tumor marker for human oral premalignant and malignant lesions. Int J Oncol 5: 955-960, 1994.
82. Grandis JR and Tweardy DJ: Elevated levels of transforming growth factor áand epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584, 1993.
83. Cowley GP, Smith JA and Gusterson BA: Increased EGF receptors on human squamous carcinoma cell lines. Br J Cancer 53: 223-239, 1986.
84. Yamamoto T and Kamata N: High incidence of amplification of the epidermal growth factor receptor genes in human squamous carcinoma cell lines. Cancer Res 46: 414-416, 1986.
85. Ozanne B, Richards CS, Hendler F, Bums D and Gusterson B: Overexpression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol 149:9-14, 1986.
86. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS and Berger WH: Synthesis of mRNAs for transforming growth factor α and β and epidermal growth factor receptor by human tumours. Cancer Res 47: 707-712, 1987.
87. Eisbruch A, Blick M, Lee JS, Sacks PG and Gutterman J: Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumours. Cancer Res 47: 3603-3605, 1987.
88. Partridge M, Gullick WJ, Langdon JD and Sherriff M: Expression of epidermal growth factor receptor on oral squamous cell carcinoma. Brit J Oral Maxillofac Surg 26: 381-389, 1988.
89. Partridge M, Green MR, Langdon JD and Feldman M: Production of TGF-α and TGF-β by cultured keratinocytes skin and oral squamous cell carcinomas - potential autocrine regulation of normal and malignant epithelial cell proliferation. Br J Cancer 60: 542-548, 1989.
90. Bergler W, Bier H and Ganzer U: The expression of epidermal growth factor receptors in the patients with oral cancer. Arch Otorhinolaryngol 246: 121-125, 1989.
91. Ishitoya J, Toriyama M, Oguchi N, Kitamura K, Ohshima M, Asano K and Yamamoto T: Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br J Cancer 59: 559-562, 1989.
92. Maxwell SA, Sacks PG, Gutterman JU and Gallick GE: Epidermal growth factor receptor protein tyrosine kinase activity in human cell lines established from squamous cell carcinomas of the head and neck. Cancer Res 49: 1130-1137, 1989.
93. Hendler FJ, Shum-Siu A, Oeschsli M, et al: Increased EGF-R1 binding predicts a poor survival in squamous tumours. Cancer Cells 7: 347-351, 1989.
94. Tadokoro K, Ueda M, Ohshima T, Fujita K, Rikimaru K, Takashashi N, Enomoto S and Tschuchida N: Activation of oncogenes in human oral cancer cells: a novel codon 13 mutation of c-Ha-ras-1 and concurrent amplifications of c-erbB-1 and c-myc. Oncogene 4: 499-505, 1989.
95. Weichselbaum RR, Dunphy EJ, Beckett MA, Tybor AG, Moran WJ, Goldman ME, Vokes EE and Panje WR: Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck 11: 437-442, 1989.
96. Sakai H, Kawano K, Okamura K and Hashimoto N: Immunohistochemical localization of c-myc and EGF receptor gene products in oral squamous cell carcinoma. J Oral Pathol Med 19: 1-4, 1990.
97. Somers KD, Cartwright SL and Schechter GL: Amplification of the Int-2 gene in human head and neck squamous cell carcinomas. Oncogene 5: 915-920, 1990.
98. El-Zayat EAA, Pingree TG, Mock PM, et al: Epidermal growth factor receptor amplification in head and neck cancer. Cancer J 4: 375-379, 1991.
99. Yin XY, Donovanpeluso M, Whiteside TL, et al: Gene amplification and gene dosage in cell lines derived from squamous cell carcinoma of the head and neck. Genes Chromosom Cancer 3: 443-454, 1991.
100. Kawamoto T, Sato JD, Polikoff ALJ, Sato GH and Mendelsohn J: Growth stimulation of A431 cells by epidermal growth factor: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80: 1337, 1983.
101. Kawamoto T, Takahashi K, Nishi M, Kimura T, Matsumura T and Taniguchi S: Quantitative assay of epidermal growth factor receptor in human squamous cell carcinomas of the oral region by an avidin-biotin method. Jpn J Cancer Res 82: 403-410, 1991.
102. Game SM, Stone A, Scully C and Prime SS: Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF-β receptor expression and altered responses to these growth factors. Carcinogenesis 11: 965-973, 1990.
103. Riviere A, Wilckens C and Loning T: Expression of c-erbB-2 and c-myc in squamous epithelia and squamous cell carcinomas of the head and neck and the lower female genital tract. J Oral Pathol Med 19: 408-413, 1990.
104. Riviere A, Becker J and Loning T: Comparative investigation of c-erbB-2/neu expression in head and neck tumors and mammary cancer. Cancer 67: 2142-2149, 1991.
105. Kearsley JH, Leonard JH, Walsh M and Wright GR: A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology 23: 189-194, 1991.
106. Leonard JH, Kearsley JH, Chenevix-Trench G and Hayward NK: Analysis of gene amplification in head and neck squamous cell carcinomas. Int J Cancer 48: 511-515, 1991.
107. Santini J, Formento JL, Frauncoual M, Milano G, Schneider M, Dassonville O and Demard E: Characterization, quantification and potential clinical value of epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13: 132-139, 1991.
108. Talacko AA, Shirlaw PJ and Johnson NW: Growth factors and their receptors as markers of the high risk lesion, with special reference to epidermal growth factors. In: Risk Markers for Oral Diseases. Oral Cancer. Detection of patients and lesions at risk. Johnson NW (ed). Vol. 2. Cambridge University Press, Cambridge, pp29-316, 1991.
109. Li B, Wang M, Wen Y and Chen J: ErbB oncogene in human oral squamous cell carcinomas. Hua-His-I-Ko-Ta-Hsueh-Hsueh-Pao 23: 284-287, 1992.
110. Christensen ME, Therkildscn MH, Hansen BL, Albeck H, Hansen GN and Bretlau P: Epidermal growth factor receptor expression on normal oral mucosa, dysplastic epithelium and squamous cell carcinomas. Eur Arch Oto-rhino-laryngol 249: 243-247, 1992.
111. Rikimaru K, Tadokoro K, Yamamoto T, Enomoto S and Tsuchida N: Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck. Head Neck 14: 8-13, 1992.
112. Saranath D, Panchal RG, Nair R, Mehta AR, Sanghavi VD and Deo MG: Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer. Oral Oncol Eur J Cancer 28B: 139-143, 1992.
113. Yamada T, Takagi M and Shioda S: Evaluation of epidermal growth factor receptor in squamous cell carcinoma of the oral cavity. Oral Surg Oral Med Oral Pathol 73: 67-70, 1992.
114. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F and Milano G: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 10: 1873-1878, 1993.
115. Irish JC and Bernstein A: Oncogenes in head and neck cancer. Laryngoscope 103:42-52, 1993.
116. Wilson JA, Rogers MJC, Hawkins RA, Gilmour HM and Maran AGD: Epidermal growth factor receptors and oestrogen receptors in the head and neck. Clin Otolaryngol 18: 66-68, 1993.
117. Prime SS, Game SM, Mathews JB, Stone A, Donnelly MJ, Yeudall WA, Patel V, Sposto R, Silverthorne A and Scully C: Epidermal growth factor and transforming growth factor α characteristics of human oral carcinoma cell lines. Br J Cancer 69: 8-15, 1994.
118. Stanton P, Richards S, Reeves J, Nikolic M, Edington K, Clark L, Robertson G, Souter D, Mitchell R, Hendler FJ, Cooke T, Parkinson EK and Ozanne BW: Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br J Cancer 70: 427-433, 1994.
119. Kannan S, Balaram P, Chandran BJ, Pillai MR, Mathew B and Nair MK: Co-expression of ras p21 and epidermal growth factor receptor during various stages of tumour progression in oral mucosa. Tumor Biol 15: 73-81, 1994.
120. Storkel S, Reichart T, Reiffen KA and Wagner W: EGFR and PCNA expression in oral squamous cell carcinomas - a valuable tool in estimating the patient's prognosis. Oral Oncol Eur J Cancer 29B: 273-277, 1993.
121. Bergler W, Petroianu G, Juncker C and Hormann K: Correlation of transforming growth factor áand epidermal growth factor receptor in oropharyngeal carcinomas. Acta Oto-laryngol 116: 486-489, 1996.
122. Shin DM, Ro JY, Hong WK and Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153-3159, 1994.
123. Osella P, Carlson A, Wyandt H and Milungky A: Cytogenetic studies of eight squamous cell carcinomas of the head and neck. Deletion of 7q, a possible primary chromosomal event. Cancer Genet Cytogenet 59: 73-78, 1992.
124. Kiaris H, Spandidos DA, Jones AS and Field JK: Loss of heterozygosity and microsatellite instability of the H-ras gene in cancer of the head and neck. Int J Oncol 5: 579-582, 1994.
125. Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, Tsuruta K, Miyaki M and Nakamura Y: Frequent loss of heterozygosity on chromosome 8p in hepatocellular carcinoma, colorectal cancer and lung cancer. Cancer Res 52: 5368-5372, 1992.
126. Fujiwara Y, Emi M, Ohata H, Kato Y, Nakajima T, Mori T and Nakamura Y: Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 53: 1172-1174, 1993.
127. Knowles MA, Shaw ME and Proctor AJ: Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene 8: 1357-1364, 1993.
128. Trapman J, Sleddens HF, van der Weiden MM, Dinjins WN, Konig JJ, Schroder FH, Faber PW and Bosman FT: Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 54: 6061-6064, 1994.
129. Eversole LR and Sapp JP: c-myc oncoprotein expression in oral precancerous and early cancerous lesions. Oral Oncol Eur J Cancer 29B: 131-135, 1993.
130. Spandidos DA, Lamothe A and Field JK: Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. Anticancer Res 5: 221-224, 1985.
131. Yokota J, Tsuwetsugu-Yokota V, Battifora H, Le Febre C and Cline JJ: Alterations of myc, myb and Ha-ras proto-oncogene in cancers are frequent and show clinical correlations. Science 231: 261-267, 1986.
132. Saranath D, Panchal RG, Nair R, Mehta AR, Sanghavi V, Sumegi J, Klein G and Deo MG: Oncogene amplification in squamous cell carcinoma of the oral cavity. Jpn J Cancer Res 80: 430-437, 1989.
133. Kawano SH, Okamura K and Hashimoto N: Immunohistochemical localization of c-myc oncogene product and EGF receptor in oral squamous cell carcinoma. J Oral Pathol Med 19: 1-4, 1990.
134. Merritt DW, Weissler MC, Turk BF and Gilmer TM: Oncogene amplification in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 116: 1394-1398, 1990.
135. Muller D, Millon R, Eber M, Abecassis J and Methlin G: Expression des oncogenes c-erbB-2 et c-myc dans des tumeurs humaines des voies aerodigestives superieures. Bull Cancer 77: 535, 1990.
136. Haughey BH, von Hoff DD, Windle BE, Wahl G and Mock PM: C-myc oncogene copy number in squamous carcinoma of the head and neck. Amer J Otolaryngol 13: 168-171, 1992.
137. Field JK: The role of oncogenes and tumour-suppressor genes in the aetiology of oral, head and neck squamous cell carcinoma. J R Soc Med 88: 9-35, 1995.
138. Rodrigo JP, Lazo PS, Ramos S, et al; MYC amplification in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 122: 504-507, 1996.
139. Gapany M, Pavelic ZP, Kelley DJ, Pavelic L, Gapany SR, Craven JM, Stambrook PJ and Gluckman JL: Immunohistochemical detection of c-myc protein in head and neck tumors. Arch Otolaryngol Head Neck Surg 120: 255-259, 1994.
140. Muller D, Millon R, Lidereau R, Engelmann A, Bronner G, Flesch H, Eber M, Methlin G and Abecassis J: Frequent amplification of 11q13 DNA markers is associated with lymph node involvement in human head and neck squamous cell carcinomas. Oral Oncol Eur J Cancer 30B: 113-120, 1994.
141. van der Reit P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W and Sidransky D: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54: 1156-1158, 1994.
142. El-Naggar AK, Hurr K, Batsakis JG, Luna MA, Goepfert H and Huff V: Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res 55: 2656-2659, 1995.
143. Rowley H, Jones AS and Field JK: Chromosome 18: a possible site for a tumour suppressor gene deletion in squamous cell carcinoma of the head and neck. Clin Otolaryngol 20: 266-271, 1995.
144. Mead LJ, Gillespie MT, Irving LB and Campbell LJ:-Homozygous and hemizygous deletions of 9p centromeric to the interferon genes in lung cancer. Cancer Res 54: 2307-2309, 1994.
145. Nobori T, Miura K, Wu DJ, Lois A, Takabayaski K and Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-755, 1994.
146. Neville EM, Stewart MP, Myskow M, Donnelly RJ and Field JK: Loss of heterozygosity at 9p23 defines a novel locus in nonsmall cell lung cancer. Oncogene 11: 581-585, 1995.
147. Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin SB and Sidransky D: Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res 54: 2322-2326, 1994.
148. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T and Takahashi T: In vivo occurrence of p!6 (MTS-1) and p15 (MTS-2) alterations preferentially in non-small cell lung cancers. Cancer Res 55: 514-517, 1995.
149. Hosokawa Y and Arnold A: Cyclin D1-PRAD-1 as a central target in oncogenesis. J Lab Clin Med 127: 246-252, 1996.
150. Cairns P: Rates of p16 (MTS-1) mutations in primary tumours with 9p loss. Science 265: 415-416, 1994.
151. Matsuda H, Konishi N, Hiasa Y, Hayashi I, Tsuzuki T, Tao M, Kitahori Y, Yoshioka N, Kirita T and Sugimura M: Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 25: 232-238, 1996.
152. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS-1 in human cancers. Nature Med 1: 686-692, 1995.
153. Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, Drum MA, Pastakia B, McBride OW, Kase R, Greene M, Mulvihill JJ and Bale AE: Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 69: 111-117, 1992.
154. Goudie DR, Yuille MAR, Leversha MA, Furlong RA, Carter NP, Lush MJ, Affara NA and Ferguson-Smith MA: Multiple selfhealing squamous epitheliomata (ESS1) mapped to chromosome 9p22-q31 in families with common ancestry. Nature Genet 3: 165-169, 1993.
155. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE and Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994.
156. Zhang S-Y, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunga S, Nobori T, Carson DA, Ridge JA and Goodrow TL: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54: 5050-5053, 1994.
157. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund JE and Sidransky D: Rates of p16 (MTS-1) mutations in primary tumors with 9p loss. Science 265: 415-416, 1994.
158. Yeudall WA, Crawford RY, Ensley JD and Robbins KC: MTS-1/CDK41 is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 15: 2683-2686, 1994.
159. Ahang S, Klein-Szanto AJP, Sauter ER, et al: Higher frequency of alterations in p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54: 5050-5053, 1994.
160. Enders GH, Koh J, Missero C, Rustgi AK and Harlow E: p16 inhibition of transformed and primary squamous epithelial cells. Oncogene 12: 1239-1245, 1996.
161. Kiaris H, Spandidos DA, Jones AS, Vaughan ED and Field JK: Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br J Cancer 72: 123-128, 1995.
162. Field JK, Yiagnisis M, Spandidos DA, Gosney JR, Papadimitriou K, Vaughan ED and Stell PM: Low levels of ras p21 oncogene expression correlates with clinical outcome in head and neck squamous cell carcinoma. Eur J Surg Oncol 18: 168-176, 1992.
163. Sheng ZM, Barrois M, Klijanienko J, Micheau C, Richard JM and Riou G: Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. Br J Cancer 62: 398-404, 1990.
164. Bazopoulou-Kyrkanidou E, Garas JI, Angelopoulos AP and Pandis N: Karyotypic abnormalities of squamous cell carcinoma of the oral cavity. J Oral Pathol 12: 167-176, 1983.
165. Zaslav AL, Stamberg J, Steinberg GM, Lin YJ and Abramson A: Cytogenetic analysis of head and neck carcinomas. Cancer Genet Cytogenet 56: 181-187, 1991.
166. Berenson JR, Yang J and Mickel RA: Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas. Oncogene4: 111-11116, 1989.
167. Schuuring E, Verhoeven E, Mool WJ and Michalides RJAM: Identification and cloning of 2 overexpressed genes, U21B31/ PRAD-1 and EMS-1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 7: 355-361, 1992.
168. Lammie GA, Fantl V, Smith R, Schuuring ED, Brookes S and Michalides R: D11S287, a purative oncogene in chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BDL-I. Oncogene 6: 439-444, 1991.
169. Lammie GA and Peters G: Chromosome 11q1S abnormalities in human cancer. Cancer Cells 3: 413-420, 1991.
170. Klijanienko J, Bianchi AB, Cvitkovic E, Janot F, Luboinski B and Conti CJ: Unexpected PRAD-1 amplification in multiple simultaneous localizations of squamous cell carcinoma of the head and neck. Eur J Cancer 29: 563-564, 1993.
171. Williams ME, Gaffey MJ, Weiss LM, Wilczynski SP, Schuuring E and Levine PA: Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 119: 1238-1243, 1993.
172. Callender T, El-Naggar AK, Lee MS, Frankenthaler R, Luna MA and Batsakis JG: PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 74: 152-158, 1994.
173. Lucas JM, Mountain RE, Gramza AW, Schuller DE, Wilkie NM and Lang JC: Expression of cyclin D1 in squamous cell carcinomas of the head and neck. Int J Oncol 5: 469-472, 1994.
174. Parise O, Janot F and Guerry R: Chromosome 11q13 gene amplifications in head and neck squamous cell carcinomas: relation with lymph node invasion. Int J Oncol 5: 309-313, 1994.
175. Gaffey MJ, lezzoni JC, Meredit SD, et al: Cyclin D1 (PRAD-1, CCND1) and glutathione-S-transferase π gene expression in head and neck squamous cell carcinoma. Hum Pathol 26: 1221-1226, 1995.
176. Volling P, Jungejulsing M, Jucker M, Stutzer H, Diehl V and Tesch H: Coamplification of the hst and bcl-1 oncogenes in advanced squamous cell carcinomas of the head and neck. Eur J Cancer 29A: 383-389, 1993.
177. Zhou DJ, Casey G and Cline MJ: Amplification of human Int-2 in breast cancers and squamous carcinomas. Oncogene 2: 279-282, 1988.
178. Bartkova J, Lukas J, Muller H, et al: Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 55: 949-956, 1995.
179. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E and Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55: 975-978, 1995.
180. Lovec H, Sewing A, Lucibello FC, Muller R and Moroy T: Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9: 323-326, 1994.
181. Azuma M, Furumoto N, Kawamata H, Yoshide H, Yanagawa T, Yura Y, Takegawa Y and Sato M: The relation of ras oncogene product p21 expression to clinicopathological status and clinical outcome in squamous cell head and neck cancer. Cancer J 1: 375-380, 1987.
182. Saranath D, Bhoite LT, Mehta AR, Sanghavi V and Deo MG: Loss of allelic heterozygosity at the harvey ras locus in human oral carcinomas. J Cancer Res Clin Oncol 117: 484-488, 1991.
183. Saranath D, Chang SE, Bhoite LT, et al:. High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 63: 573-578, 1991.
184. McDonald JS, Jones H, Pavelic ZP, Pavelic LJ, Stambrook PJ and Gluckmari JL: Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 23: 342-346, 1994.
185. Freer E, Savage NW, Seymour GJ, Dunn TL, Lavin MF and Gardiner RA: Ras oncogene expression in normal and malignant oral mucosa. Aust Dent J 35: 141-146, 1990.
186. Rumsby G, Carter RL and Gusterson BA: Low incidence of ras oncogene activation in human squamous cell carcinomas. Br J Cancer 61: 365-368, 1990.
187. Chang SE, Bhatia P, Johnson NW, et al: Ras mutations in United Kingdom examples of oral malignancies are infrequent. Int J Cancer 48: 409-412, 1991.
188. Warnakulasuriya KAAS, Chang SE and Johnson NW: Point mutations in Ha-ras oncogene are detectable in formalin-fixed tissues of oral squamous cell carcinomas, but are infrequent in British cases. J Oral Pathol Med 21: 225-229, 1992.
189. Clark LJ, Edington K, Swan IRC, McLay KA, Newlands WJ, Wills LC, Young HA, Johnston PW, Mitchell R, Robertson G, Soutar D, Parkinson EK and Birnie GD: The absence of Harvey ras mutations during development and progression of squamous cell carcinomas of the head and neck. Br J Cancer 68: 617-620, 1993.
190. Yeudall WA, Torrance LK, Elsegood KA, Speight P, Scully C and Prime SS: Ras gene point mutation is a rare event in premalignant tissues and malignant cells and tissues from oral mucosal lesions. Oral Oncol Eur J Cancer: 29B: 63-67, 1993.
191. Kannan S, Balaram P, Radhakrishna P, Chandran GJ and Nair MK: Immunohistochemical analysis of ras p21 expression in normal, premalignant and malignant oral mucosa. Int J Cancer 55: 700-702, 1993.
192. Field JK, Lamothe A and Spandidos DA: Clinical relevance of oncogene expression in head and neck tumours. Anticancer Res 6: 595-600, 1986.
193. Milasin JPN, Dedovic N, Nikolic Z, Petrovic D and Dimitrijevic B: High incidence of H-ras oncogene mutations in squamous cell carcinoma of lip vermilion. J Oral Pathol Med 23: 298-301, 1994.
194. Howell RE, Wong FSH and Fenwick RG: Loss of Harvey ras heterozygosity in oral squamous cell carcinoma. J Oral Pathol Med 18: 79-83, 1989.
195. Gimenez-Conti IB, Bianchi AB, Stockman SL, Conti CJ and Slaga TJ: Activating mutation of the Ha-ras gene in chemically induced tumors of the hamster cheek pouch. Mol Carcinogen 5: 259-263, 1992.
196. Yuan B, Heniford BW, Ackermann DM, Hawkins BL and Hendler FJ: Harvey ras (H-ras) point mutations are induced by 4-nitroquinoline-1-oxide in murine oral squamous epithelia, while squamous cell carcinomas and loss of heterozygosity occur without additional exposure. Cancer Res 54: 5310-5317, 1994.
197. Hashimoto Y, Kawachi E, Shudo K, Sekiya T and Sugimura T: Transforming activity of human c-H-ras-1 proto-oncogene generated by the binding of 2-amino-6-methyl-dipyrido (1,2-a:3′,2′-d)imidazole and 4-nitroquinoline N-oxide: direct evidence of cellular transformation by chemically modified DNA. Jpn J Cancer Res 78: 211-215, 1987.
198. Anderson JA, Irish JC, McLachlin CM and Ngan BY: H-ras oncogene mutation and human papillomavirus infection in oral carcinomas. Arch Otolaryngol Head Neck Surg 120: 755-760, 1994.
199. Steenbergen RDM, Hermsen MAJA, Walboomers JMM, Joenje H, Arwert F, Meijer CJLM and Snijders PJF: Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line. Cancer Res 55: 5465-5471, 1995.
200. Phelps WE, Yee CL, Munger K and Howley PM: The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53: 539-547, 1988.
201. Kuo MYP, Jeng JH, Chiang CP and Hahn LJ: Mutations of Ki-ras oncogene codon 12 in betel quid chewing-related human oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 23: 70-74, 1994.
202. Yoo GH, Xu HJ, Brennan JA, Westra W, Hruban RH, Koch W, Benedict WF and Sidransky D: Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res 54: 4603-4606, 1994.
203. Kim MS, Li S-L, Bertolami CN, Cherrick HM and Park N-H: State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res 13: 1405-1414, 1993.
204. Largey JS, Meltzer SJ, Yin J, et al: Loss of heterozygosity of p53 in oral cancers demonstrated by the polymerase chain reaction. Cancer 71: 1933-1937, 1993.
205. Tsuji T, Mimura Y, Maeda K, Ida M, Sasaki K and Shinozaki F: Numerical aberrations of chromosome 17 detected by FISH with DNA-specific probe in oral tumours. Anticancer Res 14: 1689-1693, 1994.
206. Caamano J, Zhang SY, Rosvold EA, Bauer B and Klein-Szanto AJP: p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol 142: 1131-1139, 1993.
207. Adamson R, Jones AS and Field JK: Loss of heterozygosity studies on chromosome 17 in head and neck cancer using microsatellite markers. Oncogene 9: 2077-2092, 1994.
208. Hou L, Shi D, Tu S-M, et al: Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett 65: 215-220, 1992.
209. Craven JM, Pavelic ZP, Stambrook PJ, et al: Expression of c-erbB-2 in human head and neck carcinoma. Anticancer Res 12: 2273-2276, 1992.
210. Field JK, Spandidos DA, Yiagnisis M, et al: C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 12: 613-619, 1992.
211. Brandt B, Vogt Y, Schlotter CM, et al: Prognostic relevance of aberrations in the erbB oncogenes from breast, ovarian, oral and lung cancers: double-differential polymerase chain reaction (ddPCR) for clinical diagnosis. Gene 159: 35-42, 1995.
212. Gallo O and Bianchi S: p53 expression: a potential biomarker for risk of multiple primary malignancies in the upper aerodigestive tract. Oral Oncol Eur J Cancer 31B: 53-57, 1995.
213. Deppert W: The yin and yang of p53 in cellular proliferation. Cancer Biol 5: 187-202, 1994.
214. Marx J: New link found between p53 and DNA repair. Science 266: 1321-1322, 1994.
215. Mundle SD, Kotelnikov VM, Wood NB, Coon JS, Horvath E, Taylor SG, Lafollette S, Calderelli DD, Hutchinson JC, Panje WR, Preisler HD and Raza A: Assessment of apoptosis in relation to proliferation and nutritional status of p53 gene in head and neck cancers. Int J Oncol 8: 1257-1264, 1996.
216. Culotta E and Koshland DE Jr: p53 sweeps through cancer research. Science 262: 1958-1961, 1993.
217. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
218. Field JK, Pavelic ZP, Spandidos DA, Stambrook PJ, Jones AS and Gluckman JL: The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 119: 1118-1122, 1993.
219. Raybaud-Diogene H, Tetu B, Morency R, Fortin A and Monteil RA: P53 overexpression in head and neck squamous cell carcinoma: review of the literature. Oral Oncol Eur J Cancer 32B: 143-149, 1996.
220. Burns JE, Baird MC, Clark LJ, Burns PA, Edington K, Chapman C, Mitchell R, Robertson G, Soutar D and Parkinson EK: Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br J Cancer 67: 1274-1284, 1993.
221. Chen YT, Xu L, Massey L, Zlotolow IM, Huvos AG, Garin-Chesa P and Old LJ: Frameshift and nonsense p53 mutations in squamous cell carcinoma of head and neck: non-reactivity with three anti-p53 monoclonal antibodies. Int J Oncol 4: 609-614, 1994.
222. Ranasinghe A, MacGeoch C, Dyer S, Spurr N and Johnson NW: Some oral carcinoma from Sri Lanka betel/tobacco chewers overexpress p53 oncoprotein but lack mutations in exons 5-9. Anticancer Res 13: 2065-2068, 1993.
223. Ranasinghe AW, Warnakulasuriya KAAS and Johnson NW: Low prevalence of expression of p53 oncoprotein in oral carcinomas from Sri Lanka associated with betel and tobacco chewing. Oral Oncol Eur J Cancer 29B: 147-150, 1993.
224. Xu L, Chen YT, Huvos AG, Zlotolow IM, Rettig WJ, Old LJ and Garin-Chesa P: Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol 3: 83-92, 1994.
225. Dowell SP and Ogden GR: The use of antigen retrieval for immunohistochemical detection of p53 overexpression in malignant and benign oral mucosa: a cautionary tale. J Oral Pathol Med 25: 60-64, 1996.
226. Field JK, Spandidos DA, Malliri A, Yiagnisis M, Gosney JR and Stell PM: Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 64: 573-577, 1991.
227. Gusterson BA, Anbazaghan R, Warren W, et al: Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 6: 1785-1789, 1991.
228. Brachman DG, Graves D, Yokes E, Beckett M, Haraf D, Montag A, Dunphy E, Mick R, Yandell D and Weichselbaum RR: Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 52: 4832-4836, 1992.
229. Chang Y, Lin Y, Tsai C, Shu C, Tsai M, Choo K and Liu S: Detection of mutations in p53 gene in human head and neck carcinomas by single strand conformation polymorphism analysis. Cancer Lett 67: 167-174, 1992.
230. Field JK, Spandidos DA and Stell PM: Overexpression of the p53 gene in head and neck cancer, linked with heavy smoking and drinking. Lancet 339: 502-503, 1992.
231. Field JK, Malliri A, Jones AJ and Spandidos DA: Mutations in the p53 gene at codon 249 are rare in squamous cell carcinoma of the head and neck. Int J Oncol 1: 253-256, 1992.
232. Langdon JD and Partridge M: Expression of the tumour suppressor gene p53 in oral cancer. Brit J Oral Maxillofac Surg 30: 214-220, 1992.
233. Ogden GR, Kiddie RA, Lunny DP and Lane DP: Assessment of p53 protein expression in normal, benign and malignant oral mucosa. J Pathol 166: 389-394, 1992.
234. Pavelic Z, Gluckman J, Gapany M, Reising J, Craven J, Kelley D, Pavelic L, Gapany S, Biddinger P and Strambrook P: Improved immunohistochemical detection of p53 protein in paraffin-embedded tissues reveals elevated levels in most head and neck and lung carcinomas: correlation of clinicopathological parameters. Anticancer Res 12: 1389-1394, 1992.
235. Sakai E, Rikimura K, Ueda M, et al: The p53 tumour suppressor gene and ras oncogene mutations in oral squamous cell carcinoma. Int J Cancer 52: 729-867, 1992.
236. Smith ML, Yin XY, Whiteside TL, Johnson JT, Herberman RB and Locker J: Abnormalities in the p53 gene in tumors and cell lines of human squamous cell carcinomas of the head and neck. Proc Am Assoc Cancer Res 33: abs. 387, 1992.
237. Sakai E and Tsuchida N: Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 7: 927-933, 1992.
238. Awwad S, Jaras E, Somes J, Lunec J: P53 overexpression in head and neck carcinoma and radiotherapy results. Int J Radiation Biol Phys 34: 323-332, 1996.
239. Somers KD, Merrick MA, Lopez ME, Incofnito LS, Schechter GL and Casey G: Frequent p53 mutations in head and neck cancer. Cancer Res 52: 5997-6000, 1992.
240. Watling DL, Gown AM and Coltrera MD: Overexpression of p53 in head and neck cancer. Head Neck 14: 437-444, 1992.
241. Berner A, Holm R, Naess A and Hjortdal O: p53 protein expression in squamocellular carcinomas of the lip. Anticancer Res 13: 2421-2424, 1993.
242. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, Correo R, Eby YJ, Ruppert M and Sidransky D: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53: 4477-4480, 1993.
243. Chung KY, Mukhopadyay T, Kim J, Casson A, Ro JY, Goepfert H, Hong WK and Roth JA: Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 53: 1676-1683, 1993.
244. Field JK, Malliri A, Butt SA, et al: p53 overexpression in end stage squamous cell carcinomas of the head and neck: correlates with a very poor clinical outcome. Int J Oncol 3: 431-435, 1993.
245. Matthews JB, Scully C, Jovanovic A, van der Waal I, Yeudall WA and Prime SS: Relationship of tobacco/alcohol use to p53 expression in patients with lingual squamous cell carcinomas. Oral Oncol Eur J Cancer 29B: 285-289, 1993.
246. Nishioka H, Hiasa Y, Isao H, Yoshiteru K, Kitahori Y, Konishi N and Sugimura M: Immunohistochemical detection of p53 oncoprotein in human oral squamous cell carcinomas and leukoplakias: comparison with proliferating cell nuclear antigen staining and correlation with clinicopathological findings. Oncology 50: 426-429, 1993.
247. Yin XY, Smith ML, Whiteside TL, Johnson JT, Herberman AB and Locker J: Abnormalities in the p53 gene in tumors and cell lines of human squamous-cell carcinomas of the head and neck. Int J Cancer 54: 322-327, 1993.
248. Bourhis J, Boq J, Wilson GD, Bressac B, Talobt M, Leridant AM, Dendale R, Janin N, Armand JP, Luboinski B, Malaise EP, Wibault P and Eschwege F: Correlation between p53 gene expression and tumor-cell proliferation in oropharyngeal cancer. Int J Cancer 57: 458-462, 1994.
249. Högmo A, Munck-Wikland E, Kuylenstierna R, Lindholm J and Auer G: Nuclear DNA content and p53 immunostaining in oral squamous cell carcinoma - an analysis of a consecutive 10 year material. Int J Oncol 5: 915-920, 1994.
250. Koch WM, Boyle JO, Mao L, Hakim J, Hruban RH and Sidransky D: p53 gene mutations as markers of tumor spread in synchronous oral cancers. Arch Otolaryngol Head Neck Surg 120: 943-947, 1994.
251. Gluckman JL, Stambrook PJ and Pavelic ZP: Prognostic significance of p53 protein accumulation in early stage T1 oral cavity cancer. Oral Oncol Eur J Cancer 30B: 281, 1994.
252. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK and Hittelman WN: Activation of p53 gene expression in premalignant lesions during head and neck tumonigenesis. Cancer Res 54: 321-326, 1994.
253. Zariwala M, Schmid S, Pfaltz M, Ohgaki H, Kleihues P and Schafer R: p53 gene mutations in oropharyngeal carcinomas: a comparison of solitary and multiple primary tumours and lymph-node metastases. Int J Cancer 56: 807-811, 1994.
254. Brennan JA, Boyle JO, Koch WM, Goodman SN, Hruban RH, Eby YJ, Couch MJ, Forestiere AA and Sidransky D: Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med 332: 712-717, 1995.
255. Brennan JA, Mao L, Hruban RH, Boyle JO, et al: Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med 332: 429-435, 1995.
256. Lavieille JP, Brabilla E, Riva-Lavieille C, Reyt E, Charachon R and Brambilla C: Immunohistochemical detection of p53 protein in preneoplastic lesions and squamous cell carcinoma of the head and neck. Acta Oto-laryngol 115: 334-339, 1995.
257. Nagai MA, Miracca EC, Yamamoto L, Kowalski LP and Brentani RR: TP53 mutations in upper aerodigestive squamous cell carciomas from a group of Brazilian patients. Am J Surg 170: 492-494, 1995.
258. Gasparotto D, Maestro R, Barzan L, et al: Recurrences and second primary tumours in the head and neck region: differentiation by p53 mutation analysis. Ann Oncol 6: 933-939, 1995.
259. Shintani S, Yoshihama Y, Emilio AR and MatsumuraT: Overexpression of p53 is an early event in the tumorigenesis of oral squamous cell carcinomas. Anticancer Res 15: 205-208, 1995.
260. Kusama K, Okutsu S, Takeda A, et al: P53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. J Pathol 178: 415-421, 1996.
261. Lazarus P, Stern J, Zwiebel N, Fair A, Richie JP Jr and Schantz S: Relationship between p53 mutation incidence in oral cavity squamous cell carcinomas and patient tobacco use. Carcinogenesis 17: 733-739, 1996.
262. Matsumura T, Yoshihama Y, Kimura T, Shintani S and Alcalde RE: p53 and MDM-2 expression in oral squamous cell carcinoma. Oncology 53: 308-312, 1996.
263. Munirajan AK, Tutsumi-Ishii Y, Mohanprasad BKC, et al: P53 gene mutations in oral carcinomas from India. Int J Cancer 66: 297-300, 1996.
264. Yan JJ, Tzeng CC and Jin YT: Overexpression of p53 protein in squamous cell carcinoma of buccal mucosa and tongue in Taiwan: an immunohistochemical and clinicopathological study. J Oral Pathol Med 25: 55-59, 1996.
265. Warnakulasuriya KAAS and Johnson NW: Association of overexpression of p53 oncoprotein with the state of cell proliferation in oral carcinoma. J Oral Pathol Med 23: 246-250, 1994.
266. Warnakulasuriya KAAS and Johnson NW: Expression of the tumour suppressor gene p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. J Oral Pathol Med 21: 404-408, 1992.
267. Girod SC, Krueger G and Paper HD: p53 and Ki-67 expression in preneoplastic and neoplastic lesions of the oral mucosa. Int J Oral Maxillofac Surg 22: 285-288, 1993.
268. Nees M, Homann N, Discher H, Andl T, Enders C, Harrold-Mende C, Schulmann A and Bosch FX: Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 53: 4189-4196, 1993.
269. Kaur J, Srivastava A and Ralhan R: Overexpression of p53 protein in betel- and tobacco-related human oral dysplasia and squamous cell carcinoma in India. Int J Cancer 58: 240-245, 1994.
270. Sauter ER, Cleveland D, Trock B, Ridge JA and Klein-Szanto JP: p53 is overexpressed in fifty percent of pre-invasive lesions of head and neck epithelium. Carcinogenesis 15: 2269-2274, 1994.
271. Slootweg PJ, Koole R and Hordijk GJ: The presence of p53 protein in relation to Ki-67 as cellular proliferation marker in head and neck squamous cell carcinoma and adjacent dysplastic mucosa. Oral Oncol Eur J Cancer 30B: 138-141, 1994.
272. Wood MW, Medina JE, Thompson GC, Houck JR and Min K-W: Accumulation of the p53 tumor-suppressor gene product in oral leukoplakia. Otolaryngol Head Neck Surg 111: 758-763, 1994.
273. Lazarus P, Garewal HS, Sciubba J, Zwiebel N, Calcagnotto A, Air A, Schaefer S and Richer JP Jr: A low incidence of p53 mutations in premalignant lesions of the oral cavity fron non-tobacco users. Int J Cancer 60: 458-463, 1995.
274. Regezi JA, Zarbo RJ, Regev E, Pisanty S, Silverman S and Gazit D: p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas. J Oral Pathol Med 24: 18-22, 1995.
275. Burns JE, McFarlane R, Clark LJ, Mitchell R, Robertson G, Soutar D and Parkinson EK: Maintenance of identical p53 mutations throughout progression of squamous cell carcinomas of the tongue. Oral Oncol Eur J Cancer 30B: 335-337, 1994.
276. Shin DM, Lee JS, Lippman SM, et al: P53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 519-529, 1996.
277. Sauter ER, Ridge JA, Gordon J and Elsenberg BL: p53 Overexpression correlates with increased survival in patients with squamous carcinoma of the tongue base. Am J Surg 164: 651-653, 1992.
278. Gapany M, Pavelic ZP, Gapany SR, et al: Relationship between immunohistochemically detectable p53 protein and prognostic factors in head and neck tumors. Cancer Detection Prev 17: 379-386, 1993.
279. Leedy DA, Trune DR, Kronz JD, Weidner N and Cohen JI: Tumor angiogenesis, the p53 antigen and cervical metastasis in squamous cell carcinoma of the tongue. Otolaryngol Head Neck Surg 111: 417-422, 1994.
280. Mukhopadhyay D, Chatterjee R and Chakraborty RN: Association of p53 expression with cytokinetics and HPV capsid antigen prevalence in oral carcinomas. Cancer Lett 87: 99-105, 1994.
281. Schipper JH and Kelker W: Die expression der tumor suppressorgene p53 und Rb bei patienten mit plattenepihtelkarzinomen im Kopf/Halsbereich. HNO 42: 270-274, 1994.
282. Xu L, Davidson BJ, Murty VVVS, et al: TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma lines. Int J Cancer 59: 383-387, 1994.
283. Ahomadegbe JC, Barrois M, Fogel S, et al: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumours and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10: 1217-1227, 1995.
284. Nakanishi Y, Noguchi M, Matsuno Y, Saikawa M, Mukai K, Shimosato Y and Hirohashi S: p53 expression in multicentric squamous cell carcinoma and surrounding squamous epithelium of the upper aerodigestive tract. Cancer 75: 1657-1662, 1995.
285. Nylander K, Stenling R, Gustafsson H, Zackrisson B and Roos G: p53 expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 75: 87-93, 1995.
286. Nylander K, Nilsson P, Mehle C and Roos G: p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Cancer 71: 826-830, 1995.
287. Gasparini G, Weidnere N, Maluta S, et al: Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous cells carcinoma. Int J Cancer 55: 739-744, 1993.
288. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E and Weichselbaum RR: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 53: 3667-3669, 1993.
289. Pekkola-Heino K, Servomaa K, Kiuru A and Grenman R: Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma. Acta Oto-laryngol 116: 3341-3344, 1996.
290. Boyle JO, Mao L, Brennan JA, Koch WM, Eisele DW, Saunders JR and Sidransky D: Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 168: 429-432, 1994.
291. Burns JE, Clark LJ, Yeudall WA, Mitchell R, Mackenzie K, Chang SE and Parkinson EK: The p53 status of cultured human premalignant oral keratinocytes. Br J Cancer 70: 591-595, 1594.
292. Fogel S, Ahomadegbe JC, Barrois M, et al: Incidence elevee des mutations p53 dans les tumeurs primitives et metastases dei voies aerodigestives superieures et frequente en proteine dans les epitheliums normaux. Bull Cancer 83: 227-233, 1956.
293. Shin DM, Voravud N, Ro JY, Lee JS, Hong WK and Hitteiman WK: Sequential upregulation of proliferating cell nucler antigen in head and neck tumorigenesis: a potential biomarker. J Natl Cancer Inst 85: 971-978, 1993.
294. Thomas S, Brennan J, Martel G, Frazer I, Montesano R, Sidransky D and Hollstein M: Mutations in the conserved region's of p53 are infrequent in betel-associated oral cancers from Papua New Guinea. Cancer Res 54: 3588-3593, 1994.
295. Gallo O, Bianchi S, Giovannucci-Uzzielli ML, Santoro R, Lenzi S, Salimbeni C, Abruzzese M and Alajmo E: p53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies. Br J Cancer 71: 1008-1012, 1995.
296. Field JK, Zoumpourlis V, Spandidos DA and Jones AS: P53 expression and mutations in squamous cell carcinoma of the head and neck: expression correlates with the patients use of tobacco and alcohol. Cancer Detection Prev 18: 197-208, 1994.
297. Franceschi S, Gloghini A, Maestro R, et al: Analysis of the p53 gene in relation to tobacco and alcohol in cancers of the upper aerodigestive tract. Int J Cancer 60: 872-876, 1995.
298. Kriek E, Engelse LD, Scherer E and Westra JG: Formation of DNA modifications by chemical carcinogens, identification, localization and quantification. Biochem Biophys Acta 738: 181-201, 1984.
299. Nylander K, Schildt EB, Eriksson M, Magnusson A, Mehle C and Roos G: A non-random deletion in the p53 gene in oral squamous cell carcinoma. Br J Cancer 73: 1381-1386, 1996.
300. Lee NK, Ye Y-W, Chen J, Li X, Waber PG and Nisen PD: p53, retinoblastoma and human papillomavirus in squamous cell carcinoma and adjacent normal mucosa of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 119: 1125-1131, 1991.
301. Mietz JA, Unger T, Hubregtse JM and Howley PM: The transcriptional function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 11: 5013-5020, 1992.
302. Hubbert NL, Sedman SA and Schiller JT: Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 66: 6237-6241, 1992.
303. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
304. WAF1/CIP1, gadd45, cyclins, cyclin-dependent kinases and PCNA in oral cancer. Int J Oncol 8: 21-28, 1996.
305. Kessis TD, Slebos RJ, Nelson WG, et al: Human papillomavirus 16 EB expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 90: 3988-3992, 1993.
306. Snijders PJF, van den Brule AJC, Meijer CJLM and Walboomers JMM: Papillomaviruses and cancer of the upper digestive and respiratory tracts. Curr Topics Microbiol Immunol 186: 177-198, 1994.
307. Snijders PJF, Cromme FC, van den Brule AJC, Schrijnemakers HJF, Snow GB and Walboomers JMM: Prevalence and expression of human papillomavirus in tonsillar carcinomas indicates a possible viral etiology. J Gen Virol 73: 2059-2066, 1992.
308. Snijders PJF, Scholes AGM, Hart CA, Jones AS, Vaughan ED, Woolgar JA,. Meijer CJLM, Walboomers JMM and Field JK: Prevalence of mucosotropic human papillomaviruses in squamous cell carcinomas of the head and neck. Int J Cancer 66: 1-6, 1996.
309. Lewensohn-Fuchs I, Munck-Wikland E, Berke Z, et al: Involvement of aberrant p53 expression and human papillomavirus in carcinoma of the head, neck and esophagus. Anticancer Res 14: 1281-1286, 1994.
310. Mao E-J, Schwartz SM, Daling JR, Oda D, Tickman L and Beckmann AM: Human papilloma viruses and p53 mutations in normal premalignant and malignant oral epithelia. Int J Cancer 69: 152-158, 1996.
311. Chiba I, Shindoh M, Yasuda M, Yamazak Y, Amemiya A, Sao Y, Fujinaga K, Notani K-I and Fukuda H: Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene 12: 1663-1668, 1996.
312. Liu T-J, Zhang W-W, Taylor DL, Roth JA, Goepfert H and Clayman GL: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54: 3662-3667, 1994.
313. Takahashi R, Inagaki T, Matsuwari S, Fujioka M, et al: Transfection of wild-tpe TP53 induced differentiation in human gingival carcinoma cells. Eur J Cancer 32A: 533-539, 1996.
314. Clayman GL, Liu TJ, Overholt SM, Mobley SR, Wang M, Janot F and Goepfert H: Gene therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 122: 489-493, 1996.
315. Kim SK, Fan Y, Papadimitrakopoulou V, Clayman G, Hittleman WN, Hong WK, Lotan R and Mao L: DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 56: 2519-2521, 1996.
316. Mao L and Sidransky D: Cancer screening based on genetic alterations in human tumors. Cancer Res 54 (Suppl): 1939s-1940s, 1994.
317. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F and Sidransky D: Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 91: 9871-9875, 1994.
318. El-Naggar AK, Hurr K, Huff V, Clayman GL, Luna MA and Batsakis JG: Microsatellite instabilitity in preinvasive and invasive head and neck squamous carcinoma. Am J Pathol 148: 2067-2072, 1996.
319. Vogelstein B, Fearon ER, Kearn SE, Hamilton SR, Preisinger AC, Nakamura Y and White R: Allelotype of colorectal carcinomas. Science 244: 207-211, 1989.
320. Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F and Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumours. Science 258: 812-818, 1992.
321. du Manior S, Speicher MR, Joos S, Chrock E, Popp S, Dohner H, Kovacs G, Robert-Nicoud M, Lichter P and Cremer T: Detection of complete and partial chromosome losses by comparative genomic in situ hybridization. Hum Genet 90: 590-610, 1993.
322. Speicher MR, Howe C, Crotty P, Du Manior S, Costa J and Ward DC: Comparative genomic hybridization detects deletions and amplifications in head and neck squamous cell carcinomas. Cancer Res 55: 1010-1013, 1995.
323. Matsumura K: Detection of DNA amplifications and deletions in oral
324. Soder AI, Hopman AHN, Ramaekers CS, Conradt C and Bosch FX: Distinct nonrandom patterns of chromosomal aberrations in the progression of squamous cell carcinomas of the head and neck. Cancer Res 55: 5030-5037, 1995.